Associated Papers
EGFR mutations in sinonasal squamous neoplasms: Novel hotspot for exon 20 insertions.
Srivastava K et al.
Virchows Archiv : an International Journal of Pathology, 2025
Acquired multiple EGFR mutations‑mediated resistance to a third‑generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review.
Yang F et al.
Oncology Letters, 2025
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A et al.
Cancer Science, 2025
The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.
Zwierenga F et al.
Lung Cancer (amsterdam, Netherlands), 2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Gettinger SN et al.
Jco Precision Oncology, 2024
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
Isaev K et al.
Haematologica, 2023
35734926 (PubMed )
Supplement: 2022_280900_ISAEV_TABS3_SUPPL.xlsx › Sheet1
EGFR and BRAF mutations in inverted sinonasal papilloma - a more complex landscape?
Zonnur S et al.
Virchows Archiv : an International Journal of Pathology, 2021
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Youssef O et al.
Oncotarget, 2017
Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.
Harvey NT et al.
Pathology, 2016
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Avizienyte E et al.
The Biochemical Journal, 2008
18588508 (PubMed )
Supplement: supplement_1.pdf
Select a paper to view details